Bibliography
- YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl. J. Med. (2003) 349:427–434.
- HURWITZ H, FEHRENBACHER T, CARTWRIGHT Jet al.: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a Phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as a first-line therapy in subjects with metastatic CRC. Proc. Am. Clin. Oncol Meet. (2003) 22: abstract 3646.
- UNDERINER TL, RUGGERI B, GINGRICH DE: Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr. Med. Chem. (2004) 11:731–745.
- DUMAS J, SMITH RA, LOWINGER TB: Recent developments in the discovery of protein kinase inhibitors from the urea class. Curr. Opin. Drug Disc. Den (2004) 7(5):600–616.
- TRAXLER P, ALLEGRINI PR, BRANDT R et al.: AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. (2004) 64:4931–4941.
- WILHELM SM, CARTER C, TANG L et al.: BAY-43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Canc. Res. (2004) 64:7099–7109.
- FRALEY ME, HOFFMAN WF, ARRINGTON KL et al.: Property-based design of KDR kinase inhibitors. Curr. Med. Chem. (2004) 11:709–719.
- SAWYERS CL: Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell (2002) 1(5):413–415.
- BECK S, DALLOB A, DAVIS Let al.: Pharmacodyanamic evaluation of an indolyl quinoline KDR/Flt-3 kinase inhibitor in normal healthy volunteers. Am. Assoc. Cancer Res. Meet. (2004) 95: abstract 2129.
- BILODEAU MT, RODMAN LD, MCGAUGHEY GB et al.: The discovery of N-(1,3-thiazol-2-yfipyridin-2-amines as potent inhibitors of KDR kinase. Bioorg Med. Chem. Lett. (2004) 14:2941–2945.
- EAMES J, WARREN S: Synthesis of cyclic sulfides and allylic sulfides by phenylsulfanyl (PhS-)migration of 0-hydroxy sulfides. J. Chem. Soc. Perkin Trans. (1999):2783–2790.
- CHOUDHURY PK, ALMENA J, FOUBELO F, YUS M: New homologation of 2-hydroxy and 2-mercapto benzylic alcohols. Tetrahedron (1997) 53(51):17373–17382.
- ROLLIN P: One-step stereospecific conversion of alcohols into dithiocarbamates: a smooth pathway for the introduction of a sulphur functionality. Tetrahedron Lett. (1986) 27(35):4169–4170.
- OGILVIE DJ, KENDREW J, BARRY ST et al.: AZD2171, a highly potent inhibitor of VEGF receptor signaling in primary human endothelial cells, exhibits broad-spectrum activity in tumor xenograft models. Am. Assoc. Cancer Res. Meet. (2004) 95: abstract 4553.
- TAGUCHI E, NAKAMURA K, TAKAHASHI K et al.: A novel orally active inhibitor of VEGF receptor tyrosine kinases KRN951: anti-angiogenic and antitumor activities against human solid tumors. Am. Assoc. Canc. Res. Meet. (2004) 95: abstract 2575.
- HARRINGTON EA, BEBBINGTON D, MOORE Jet al.: VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat. Med. (2004) 3:262–267.